SANA
Sana Biotechnology, Inc.
There isn't enough reported data to score SANA yet.
SANA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
SANA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
SANA PE Valuation
SANA has no meaningful PE right now: it lost money over the past year.
SANA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect SANA's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
SANA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.52 | +$0.45 |
| Q2 2026 | -$0.75 | +$0.31 |
| Q1 2026 | -$0.92 | -$0.04 |
| Q4 2025 | -$0.96 | +$0.20 |
| Q3 2025 | -$0.97 | +$0.42 |
| Q2 2025 | -$1.06 | +$0.08 |
| Q1 2025 | -$0.88 | +$0.64 |
| Q4 2024 | -$1.16 | +$0.30 |
SANA is still losing money, but far less than before: $0.52 per share over the past year, against $3.23 at its worst in early 2021.
SANA Quarterly Revenue
SANA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.5M | -$10.1M |
| Q2 2026 | -$34.4M | -$1.4M |
| Q1 2026 | -$37.7M | +$11.1M |
| Q4 2025 | -$33.5M | +$14.1M |
| Q3 2025 | -$29.5M | +$26.4M |
| Q2 2025 | -$33M | +$38.6M |
| Q1 2025 | -$48.8M | +$32.7M |
| Q4 2024 | -$47.6M | +$18.4M |
SANA has burned cash in almost every quarter: −$145M over the past year, against −$159M the year before.
SANA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.4% | +13.1M shares |
| 1 year | +19% | +48.3M shares |
| 3 years | +54% | +108M shares |
| 5 years | +70% | +127M shares |
| Available history | +94% | +150M shares |
SANA has 309M diluted shares, up 19% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
SANA Net Leverage
SANA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SANA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.5 | Neutral |
| Stochastic | 8.5 | Oversold |
SANA's weekly RSI is 34 (neutral) and its Stochastic is 8 (oversold).
SANA PE vs Healthcare Sector
SANA has no meaningful PE right now: it lost money over the past year.
SANA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.52 | 20% below |
| 20 week MA | $3.12 | 36% below |
| 50 week MA | $3.48 | 42% below |
| 100 week MA | $3.27 | 39% below |
| 200 week MA | $4.33 | 54% below |
SANA is in a downtrend: it's below all five of its weekly moving averages, and 54% below its 200-week average.
SANA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $39.1 | $16.4 | -58% |
| 2022 | $16.4 | $3.39 | -79% |
| 2023 | $3.39 | $4.08 | +20% |
| 2024 | $4.08 | $1.61 | -61% |
| 2025 | $1.61 | $4.41 | +174% |
| 2026 YTD | $4.41 | $2.01 | -54% |
SANA's yearly returns have swung widely, from +174% in 2025 to −79% in 2022. It's down 54% so far in 2026.